Barriers to care for chronic hepatitis C in the direct-acting antiviral era: a single-centre experience
Authors:
Open Access
- 20 December 2017
- journal article
- research article
- Published by BMJ in BMJ Open Gastroenterology
- Vol. 4 (1) , e000181
Abstract
Background Cure rates for chronic hepatitis C have improved dramatically with direct-acting antivirals (DAAs), but treatment barriers remain. We aimed to compare treatment initiation rates and barriers across both interferon-based and DAA-based eras. Methods We conducted a retrospective cohort study of all patients with chronic hepatitis C seen at an academic hepatology clinic from 1999 to 2016. Patients were identified to have chronic hepatitis C by the International Classification of Diseases, Ninth Revision codes, and the diagnosis was validated by chart review. Patients were excluded if they did not have at least one visit in hepatology clinic, were under 18 years old or had prior treatment with DAA therapy. Patients were placed in the DAA group if they were seen after 1 January 2014 and had not yet achieved virological cure with prior treatment. All others were considered in the interferon group. Results 3202 patients were included (interferon era: n=2688; DAA era: n=514). Despite higher rates of decompensated cirrhosis and medical comorbidities in the DAA era, treatment and sustained virological response rates increased significantly when compared with the interferon era (76.7% vs 22.3%, PConclusions Despite higher rates of medical comorbidities in the DAA era, considerable treatment challenges remain including cost, loss to follow-up and ethnic disparities.Keywords
This publication has 27 references indexed in Scilit:
- Implementation of baby boomer hepatitis C screening and linking to care in gastroenterology practices: a multi-center pilot studyBMC Gastroenterology, 2016
- Hepatitis C Disease Burden in the United States in the era of oral direct‐acting antiviralsHepatology, 2016
- Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO networkJournal of Viral Hepatitis, 2016
- Chronic hepatitis CEuropean Journal of Gastroenterology & Hepatology, 2016
- Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised studyThe Lancet, 2014
- Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV InfectionNew England Journal of Medicine, 2014
- Sofosbuvir for Previously Untreated Chronic Hepatitis C InfectionNew England Journal of Medicine, 2013
- Diagnosis, management, and treatment of hepatitis C: An update # † ‡Hepatology, 2009
- Racial Differences in the Evaluation and Treatment of Hepatitis C Among Veterans: A Retrospective Cohort StudyAmerican Journal of Public Health, 2008
- Diagnosis, management, and treatment of hepatitis C†Hepatology, 2004